<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pelvic inflammatory disease: Long-term complications</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pelvic inflammatory disease: Long-term complications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pelvic inflammatory disease: Long-term complications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey F Peipert, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tessa Madden, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pelvic inflammatory disease (PID) refers to infection of the female upper genital tract leading to one or more of the following: endometritis, salpingitis, oophoritis, pelvic peritonitis, and perihepatitis [<a href="#rid1">1</a>]. Prompt diagnosis and treatment are important to reduce the risk of both short- and long-term complications. However, even with timely treatment and clinical improvement in symptoms, long-term sequelae (eg, chronic pelvic pain, infertility, ectopic pregnancy) frequently occur. The mechanism by which this occurs is thought to be secondary to scarring and adhesion formation that accompanies healing of infection-damaged tissues. </p><p>Long-term complications of PID will be reviewed here; other issues related to PID are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7580.html" rel="external">"Pelvic inflammatory disease: Pathogenesis, microbiology, and risk factors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents"</a>.)</p><p></p><p class="headingAnchor" id="H21129257"><span class="h1">PREDICTORS AND DISEASE RECURRENCE</span><span class="headingEndMark"> — </span>Signs and symptoms associated with acute PID (eg, pelvic pain, documented infection, endometritis) are poor predictors of the eventual development of chronic sequelae [<a href="#rid2">2</a>]. Furthermore, clinical and/or microbiologic cure of acute disease does not preclude development of the long-term complications (eg, chronic pain, infertility, ectopic pregnancy). Therefore, clinicians should not assume that patients with a complete recovery from PID have avoided the increased risk of long-term complications.</p><p>Patients with a history of PID are also at increased risk of recurrence. In a secondary analysis of over 800 patients with mild to moderate PID from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) randomized trial, recurrent PID at 35 and 84 months occurred in 15 and 21 percent of patients, respectively [<a href="#rid3">3</a>]. Adolescents compared with adults were 50 percent more likely to experience a recurrence and had shorter times to recurrence (hazard ratio [HR] 1.54, 95% CI 1.03-2.3]). Limitations of this study include that recurrent PID was self-reported (although verified with medical records when available) and most patients in this study were uninsured or had public insurance; other populations may have different rates of recurrence.</p><p class="headingAnchor" id="H4"><span class="h1">CHRONIC PELVIC PAIN</span><span class="headingEndMark"> — </span>As many as one-third of patients with PID develop chronic pelvic pain, defined as menstrual or non-menstrual pain of at least six months' duration that occurs below the umbilicus and is severe enough to cause functional disability [<a href="#rid4">4-6</a>]. While the precise etiology is unknown, the pain may result from scarring and adhesions that develop from inflammation related to the infectious process. (See  <a class="medical medical_review" href="/d/html/5490.html" rel="external">"Chronic pelvic pain in nonpregnant adult females: Causes", section on 'Common'</a>.)</p><p>In studies using data from the PID evaluation and clinical health (PEACH) randomized trial, recurrent PID was the strongest predictor for the development of chronic pelvic pain (odds ratio [OR] 2.84, 95% CI 1.07-7.54) [<a href="#rid7">7</a>]. Other predictors included smoking (OR 1.65, 95% CI 1.01–2.71) and a lower (worse) mental health score (OR 2.71, 95% 1.69–4.34). Similarly, in a subsequent study, patients with versus without recurrent PID were over four times more likely to report chronic pelvic pain (adjusted OR 4.2, 95% CI 2.8-6.2) [<a href="#rid8">8</a>].</p><p>PID may result in painful bladder syndrome. In a case-control study evaluating the correlation between painful bladder syndrome and PID, patients with bladder pain syndrome/interstitial cystitis (449 patients) compared with controls were more likely to have a history of PID (41.7 versus 15.4 percent, OR 3.69, 95% CI 2.89-4.71) [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/8085.html" rel="external">"Interstitial cystitis/bladder pain syndrome: Clinical features and diagnosis", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H2155643890"><span class="h1">TUBAL DAMAGE</span><span class="headingEndMark"> — </span>PID can cause permanent injury to the fallopian tube, especially the endosalpinx. Changes to the fallopian tube, including loss of ciliary action, fibrosis, and occlusion can lead to hydrosalpinx, tubal infertility, and ectopic pregnancy [<a href="#rid10">10</a>]. </p><p class="headingAnchor" id="H462853794"><span class="h2">Hydrosalpinx</span><span class="headingEndMark"> — </span>Patients with PID may develop a hydrosalpinx, a postinflammatory process in which the damaged fallopian tube can become blocked, fill with sterile fluid, and become enlarged. Even after PID resolves, the hydrosalpinx remains. Damage to the fallopian tube from previous surgery or adhesions can also result in hydrosalpinx. </p><p>Hydrosalpinx may be associated with pain or may be asymptomatic; some asymptomatic patients present with tubal factor infertility. </p><p>In patients undergoing in vitro fertilization (IVF), hydrosalpinx has negative consequences on the rates of pregnancy, implantation, early pregnancy loss, preterm birth, and live delivery [<a href="#rid11">11,12</a>]. Thus, salpingectomy with removal of the hydrosalpinx is often performed prior to IVF to improve outcomes. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5448.html" rel="external">"Female infertility: Treatments", section on 'Salpingectomy for hydrosalpinx'</a>.)</p><p>Imaging findings of hydrosalpinx and the progression to pyosalpinx are discussed separately. (See  <a class="medical medical_review" href="/d/html/3262.html" rel="external">"Hysterosalpingography", section on 'Hydrosalpinx'</a> and  <a class="medical medical_review" href="/d/html/7589.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of tubo-ovarian abscess", section on 'Progression of infection'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Infertility</span><span class="headingEndMark"> — </span>Tubal damage caused by PID increases the risk of infertility, the prevalence of which appears to be increased severalfold. In a study using data from the PID evaluation and clinical health (PEACH) randomized trial, recurrent PID was associated with an almost twofold increase in infertility (adjusted OR 1.8, 95% CI 1.2-2.8) [<a href="#rid8">8</a>]. Similarly, in a prospective study of 1760 Swedish patients with suspected PID who underwent diagnostic laparoscopy and desired pregnancy, more patients with laparoscopically-confirmed PID (group 1) compared with normal laparoscopic findings (group 2) failed to conceive (16 versus 2.7 percent); patients were followed for up to 25 years [<a href="#rid13">13</a>]. Tubal factor accounted for 68 percent of infertility diagnoses; no patients in group 2 had tubal factor infertility.</p><p>Subclinical PID, defined as histologic endometritis with no symptoms of acute PID, also appears to decrease subsequent fertility, even in patients who are treated for chlamydia, gonorrhea, and bacterial vaginosis [<a href="#rid14">14</a>]. Treatment of cervicitis without endometritis does not appear to have this effect. </p><p>Infertility after acute PID depends upon multiple factors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chlamydial infection</strong> – Infection with <em>Chlamydia trachomatis</em> increases the risk of tubal factor infertility. In one prospective study including 194 patients with tubal factor infertility seeking care in an infertility clinic, approximately one in four patients had serum antibodies to <em>C. trachomatis</em> [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent1">Furthermore, serum titers of <em>C. trachomatis</em> antibodies correlate inversely with pregnancy rates [<a href="#rid15">15,16</a>]. In one study of 443 patients with symptoms and signs of PID in whom blood samples were available, patients with the highest and lowest antibody titers had pregnancy rates of 59.6 and 73 percent, respectively, at seven years postinfection [<a href="#rid17">17</a>]. These data suggest that infertility after PID may result, at least in part, from the hostꞌs immune response to chlamydial infection, and a high titer may be associated with a greater inflammatory response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Mycoplasma genitalium</em></strong><em> </em>– Infection with <em>Mycoplasma genitalium</em>, a bacteria associated with non-specific urethritis in males and acute cervicitis and PID in females, also increases the risk of infertility. In a prospective study of over 460 females attempting conception after discontinuation of contraception, those with positive compared with negative <em>M. genitalium</em> serology had longer times to conception (8.5 versus 4.8 months [median]) and higher rates of infertility (31.7 versus 20 percent) at 12 months [<a href="#rid18">18</a>]. <em>M. genitalium </em>also appeared to be a<em> </em>better predictor of infertility than <em>C. trachomatis</em> serology. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delay in initiating treatment</strong> – Patients with PID who delay seeking care are at increased risk for infertility. In one cohort study including patients with PID, patients who delayed seeking treatment for ≥3 days compared with seeking care in a timely manner were more likely to be diagnosed with infertility (19.2 versus 8.3 percent) [<a href="#rid19">19</a>]. This association was highest in patients with chlamydial infection (17.8 percent); no patients with chlamydia who sought care promptly had impaired fertility.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increasing number of PID episodes</strong> – Increasing number of PID episodes is also associated with increased infertility. In a classic review of PID in resource-abundant countries, pregnancy rates after one, two, or three or more episodes of PID were 89, 77, and 46 percent, respectively [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>More severe infection</strong> – More severe PID is also inversely related to the probability of live birth. In another classic review of patients with PID and who desired pregnancy, the cumulative proportions of patients achieving a livebirth after mild, moderate, and severe PID were 90, 82, and 57 percent, respectively [<a href="#rid21">21</a>].</p><p></p><p>In patients with chronic PID, infertility may also result from diminished ovarian reserve, as reported in at least one study [<a href="#rid22">22</a>]. </p><p class="headingAnchor" id="H8"><span class="h2">Ectopic pregnancy</span><span class="headingEndMark"> — </span>Tubal damage caused by PID increases the risk of tubal pregnancy. The increased expression of certain proteins involved in implantation may also play a role in the pathophysiology [<a href="#rid23">23</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5481.html" rel="external">"Ectopic pregnancy: Epidemiology, risk factors, and anatomic sites", section on 'Pelvic inflammatory disease and other genital infections'</a>.)</p><p>In the prospective study of Swedish patients discussed above (see <a class="local">'Infertility'</a> above), patients with laparoscopically-confirmed PID compared with normal laparoscopic findings had a higher incidence of ectopic pregnancy for the first pregnancy after laparoscopy (7.8 versus 1.3 percent) [<a href="#rid13">13</a>]. The risk of ectopic pregnancy also increased with the number of episodes and severity of PID. For patients with one, two, and three episodes of PID, the ratio of ectopic pregnancy to intrauterine pregnancy was 1:15, 1:6, and 1:3, respectively. Similarly, for patients with a single episode of mild, moderate, or severe PID, the ratio of ectopic pregnancy to intrauterine pregnancy was 1:35, 1:25, and 1:5, respectively.</p><p class="headingAnchor" id="H12435232"><span class="h1">OVARIAN CANCER</span><span class="headingEndMark"> — </span>The association between PID and ovarian cancer is unclear. In a meta-analysis of 16 cohort and case-control studies, PID was associated with an increased risk of ovarian cancer (hazard ratio [HR] 1.18, 95% CI 1.13-1.22) [<a href="#rid24">24</a>]. In one study included in this meta-analysis, patients with at least five episodes of PID had a particularly high risk (HR 2.46, 95% CI 1.48-4.09) [<a href="#rid25">25</a>]. Subanalyses also showed an increase in borderline ovarian tumors (HR 1.28, 1.19–1.37; two studies) and both serous and nonserous types. In a subsequent case-control study using data from several Swedish nationwide registries, patients with ovarian cancer compared with controls had higher rates of prior PID (adjusted odds ratio [OR] 1.39, 95% CI 1.17-1.66) [<a href="#rid26">26</a>].</p><p>However, it is not known whether PID is an independent risk factor for ovarian cancer as PID increases the risk of low parity and infertility, both of which are also risk factors for ovarian cancer [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/83387.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Incidence and risk factors", section on 'Nulliparity'</a> and  <a class="medical medical_review" href="/d/html/83387.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Incidence and risk factors", section on 'Infertility and infertility treatment'</a>.)</p><p>If PID increases the risk of ovarian cancer, management with salpingectomy likely decreases this risk. In a subsequent cohort using nationwide registry-based data and including almost 100,000 patients with PID, those managed without salpingectomy compared with controls had a higher risk of developing ovarian cancer (HR 1.44, 95% CI 1.31-1.59) [<a href="#rid28">28</a>]. By contrast, patients managed with salpingectomy compared with controls had a lower risk of ovarian cancer (HR 0.55, 95% CI 0.36-0.83). The latter finding is consistent with an abundance of data demonstrating that the fallopian tubes, rather than the ovaries, are the primary site of most epithelial ovarian, fallopian tube, and peritoneal carcinomas. (See  <a class="medical medical_review" href="/d/html/91886.html" rel="external">"Opportunistic salpingectomy for ovarian, fallopian tube, and peritoneal carcinoma risk reduction", section on 'Role of the fallopian tube in carcinogenesis'</a>.)</p><p class="headingAnchor" id="H596138508"><span class="h1">ENDOMETRIOSIS</span><span class="headingEndMark"> — </span>A history of PID may be associated with endometriosis. In a meta-analysis of 14 studies (over 740,000 patients) evaluating the association between PID and endometriosis, those with versus without a history of PID had an increased risk of endometriosis (pooled odds ratio [OR] 2.7, 95% CI 1.87–3.9); the risk was also increased in a subgroup of patients with endometritis (OR 1.63, 95% CI 1.53-1.74; six studies) [<a href="#rid29">29</a>]. However, this analysis was limited by the heterogeneity of the included studies as well as a lack of consistent use of laparoscopy to confirm endometriosis. Given both PID and endometriosis cause pelvic pain, there is also the potential for misclassification. </p><p class="headingAnchor" id="H2086644794"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Prevention of PID and disease recurrence is important in reducing long-term sequelae [<a href="#rid7">7,8,20</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Condoms </strong>– Patients whose male partners consistently use condoms are less likely to acquire sexually transmitted infections (STIs), and develop recurrent PID or infertility [<a href="#rid30">30</a>].<strong> </strong>In the PID evaluation and clinical health (PEACH) randomized trial, patients with PID who subsequently acquired a lower genital tract infection were 2.3 times more likely to develop chronic pelvic pain than those who did not (adjusted odds ratio [OR] 2.3, 95% CI 1.2-3.2) [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">The use of male condoms for the prevention of STIs is discussed separately. (See  <a class="medical medical_review" href="/d/html/7595.html" rel="external">"Prevention of sexually transmitted infections", section on 'Male condom use'</a>.)</p><p></p><p>Other contraceptives may also reduce the risk of PID, but the evidence is less certain:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progestins </strong>–<strong> </strong>While progestin-based contraceptives do not protect from acquiring sexually transmitted infections, they may decrease the risk of PID. Progestin-induced thickening and increased viscosity of cervical mucus has been hypothesized to inhibit ascent of bacteria, thereby possibly providing an enhanced barrier against ascending infection. (See  <a class="medical medical_review" href="/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)", section on 'Impact on sexually transmitted infection acquisition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intrauterine Devices </strong>– The risk of PID in intrauterine device (IUD) users is low, and the risk of PID in patients with chlamydia or gonorrhea using an IUD is similar to the risk of PID in patients with chlamydia or gonorrhea who are not using an IUD. While there is some evidence that the risk of STI acquisition is lower in <a class="drug drug_general" data-topicid="93719" href="/d/drug information/93719.html" rel="external">copper IUD</a> users compared to hormonal IUD users (OR 0.34, 95% CI 0.14-0.86), this finding was no longer statistically significant in the adjusted analysis [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">The risks of PID in patients with an IUD, as well as management of patients with PID and an IUD, are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5422.html" rel="external">"Intrauterine contraception: Management of side effects and complications", section on 'Infection and/or pelvic inflammatory disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral contraceptive pills</strong> – The protective role of oral contraceptives in the acquisition of PID is controversial, with some studies reporting that use of oral contraceptives confers a protective effect against the development of chlamydial PID [<a href="#rid32">32,33</a>], while others do not [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Impact on STI acquisition'</a>.)</p><p></p><p>Other prevention strategies to reduce STIs are discussed separately. (See  <a class="medical medical_review" href="/d/html/7595.html" rel="external">"Prevention of sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H3641507583"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111629.html" rel="external">"Society guideline links: Gynecologic infectious diseases (non-sexually transmitted)"</a>.)</p><p class="headingAnchor" id="H10414288"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/17117.html" rel="external">"Patient education: Pelvic inflammatory disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical significance</strong> – Pelvic inflammatory disease (PID) refers to infection of the female upper genital tract leading to one or more of the following: endometritis, salpingitis, oophoritis, pelvic peritonitis, and perihepatitis. While prompt diagnosis and treatment are important to reduce the risk of both short- and long-term complications, long-term sequelae frequently occur. (See <a class="local">'Introduction'</a> above and <a class="local">'Predictors and disease recurrence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrence</strong> – Patients with a history of PID are at increased risk of recurrence. Adolescents are more likely than adults to experience recurrence and have shorter times to recurrence. (See <a class="local">'Predictors and disease recurrence'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term sequalae</strong> – Major long-term complications of PID include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic pelvic pain</strong> – As many as one-third of patients with PID develop chronic pelvic pain, defined as menstrual or non-menstrual pain of at least six months' duration that occurs below the umbilicus and is severe enough to cause functional disability. (See <a class="local">'Chronic pelvic pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tubal damage</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hydrosalpinx</strong> – Patients with PID may develop a hydrosalpinx, a postinflammatory process in which the damaged fallopian tube can become blocked, fill with sterile fluid, and become enlarged. Even after PID resolves, the hydrosalpinx remains. (See <a class="local">'Hydrosalpinx'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Infertility</strong> – PID can cause permanent injury to the fallopian tube, especially the endosalpinx. Risk factors for infertility after PID include presence of chlamydial or <em>Mycoplasma genitalium </em>infection, delay in initiating treatment, increased number of PID infections, and severity of infection. (See <a class="local">'Infertility'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Ectopic pregnancy</strong> – Tubal damage caused by PID increases the risk of tubal pregnancy. (See <a class="local">'Ectopic pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ovarian cancer</strong> – The association between PID and ovarian cancer is unclear; PID increases the risk of low parity and infertility, which are also risk factors for ovarian cancer. (See <a class="local">'Ovarian cancer'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endometriosis</strong> – A history of PID may be associated with endometriosis, however studies are limited, and both can cause chronic pelvic pain. (See <a class="local">'Endometriosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong>– Patients whose male partners consistently use condoms are less likely to acquire sexually transmitted infections (STIs) and develop recurrent PID or infertility. Other contraceptives (eg, progestin-only, combined oral contraceptives) may also play a protective role in the acquisition of PID, but the evidence is less certain. (See <a class="local">'Prevention'</a> above.) </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Trautmann GM, Kip KE, Richter HE, et al. Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease? Am J Obstet Gynecol 2008; 198:30.e1.</a></li><li><a class="nounderline abstract_t">Trent M, Haggerty CL, Jennings JM, et al. Adverse adolescent reproductive health outcomes after pelvic inflammatory disease. Arch Pediatr Adolesc Med 2011; 165:49.</a></li><li><a class="nounderline abstract_t">Yeh JM, Hook EW 3rd, Goldie SJ. A refined estimate of the average lifetime cost of pelvic inflammatory disease. Sex Transm Dis 2003; 30:369.</a></li><li><a class="nounderline abstract_t">Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002; 186:929.</a></li><li><a class="nounderline abstract_t">Weström L. Effect of acute pelvic inflammatory disease on fertility. Am J Obstet Gynecol 1975; 121:707.</a></li><li><a class="nounderline abstract_t">Haggerty CL, Peipert JF, Weitzen S, et al. Predictors of chronic pelvic pain in an urban population of women with symptoms and signs of pelvic inflammatory disease. Sex Transm Dis 2005; 32:293.</a></li><li><a class="nounderline abstract_t">Trent M, Bass D, Ness RB, Haggerty C. Recurrent PID, subsequent STI, and reproductive health outcomes: findings from the PID evaluation and clinical health (PEACH) study. Sex Transm Dis 2011; 38:879.</a></li><li><a class="nounderline abstract_t">Chung SD, Chang CH, Hung PH, et al. Correlation Between Bladder Pain Syndrome/Interstitial Cystitis and Pelvic Inflammatory Disease. Medicine (Baltimore) 2015; 94:e1878.</a></li><li><a class="nounderline abstract_t">Cates W Jr, Joesoef MR, Goldman MB. Atypical pelvic inflammatory disease: can we identify clinical predictors? Am J Obstet Gynecol 1993; 169:341.</a></li><li><a class="nounderline abstract_t">Camus E, Poncelet C, Goffinet F, et al. Pregnancy rates after in-vitro fertilization in cases of tubal infertility with and without hydrosalpinx: a meta-analysis of published comparative studies. Hum Reprod 1999; 14:1243.</a></li><li><a class="nounderline abstract_t">Kawwass JF, Crawford S, Kissin DM, et al. Tubal factor infertility and perinatal risk after assisted reproductive technology. Obstet Gynecol 2013; 121:1263.</a></li><li><a class="nounderline abstract_t">Weström L, Joesoef R, Reynolds G, et al. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992; 19:185.</a></li><li><a class="nounderline abstract_t">Wiesenfeld HC, Hillier SL, Meyn LA, et al. Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol 2012; 120:37.</a></li><li><a class="nounderline abstract_t">Svenstrup HF, Fedder J, Kristoffersen SE, et al. Mycoplasma genitalium, Chlamydia trachomatis, and tubal factor infertility--a prospective study. Fertil Steril 2008; 90:513.</a></li><li><a class="nounderline abstract_t">Ness RB, Trautmann G, Richter HE, et al. Effectiveness of treatment strategies of some women with pelvic inflammatory disease: a randomized trial. Obstet Gynecol 2005; 106:573.</a></li><li><a class="nounderline abstract_t">Ness RB, Soper DE, Richter HE, et al. Chlamydia antibodies, chlamydia heat shock protein, and adverse sequelae after pelvic inflammatory disease: the PID Evaluation and Clinical Health (PEACH) Study. Sex Transm Dis 2008; 35:129.</a></li><li><a class="nounderline abstract_t">Peipert JF, Zhao Q, Schreiber CA, et al. Intrauterine device use, sexually transmitted infections, and fertility: a prospective cohort study. Am J Obstet Gynecol 2021; 225:157.e1.</a></li><li><a class="nounderline abstract_t">Hillis SD, Joesoef R, Marchbanks PA, et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 168:1503.</a></li><li><a class="nounderline abstract_t">Weström L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 1980; 138:880.</a></li><li><a class="nounderline abstract_t">Lepine LA, Hillis SD, Marchbanks PA, et al. Severity of pelvic inflammatory disease as a predictor of the probability of live birth. Am J Obstet Gynecol 1998; 178:977.</a></li><li><a class="nounderline abstract_t">Cui L, Sheng Y, Sun M, et al. Chronic Pelvic Inflammation Diminished Ovarian Reserve as Indicated by Serum Anti Mülerrian Hormone. PLoS One 2016; 11:e0156130.</a></li><li><a class="nounderline abstract_t">Quintar AA, Mukdsi JH, del Valle Bonaterra M, et al. Increased expression of uteroglobin associated with tubal inflammation and ectopic pregnancy. Fertil Steril 2008; 89:1613.</a></li><li><a class="nounderline abstract_t">Piao J, Lee EJ, Lee M. Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis. Gynecol Oncol 2020; 157:542.</a></li><li><a class="nounderline abstract_t">Lin HW, Tu YY, Lin SY, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 2011; 12:900.</a></li><li><a class="nounderline abstract_t">Jonsson S, Jonsson H, Lundin E, et al. Pelvic inflammatory disease and risk of epithelial ovarian cancer: a national population-based case-control study in Sweden. Am J Obstet Gynecol 2024; 230:75.e1.</a></li><li><a class="nounderline abstract_t">Ingerslev K, Hogdall E, Schnack TH, et al. The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis. Infect Agent Cancer 2017; 12:25.</a></li><li><a class="nounderline abstract_t">Falconer H, Yin L, Salehi S, Altman D. Association between pelvic inflammatory disease and subsequent salpingectomy on the risk for ovarian cancer. Eur J Cancer 2021; 145:38.</a></li><li><a class="nounderline abstract_t">Ye H, Tian Y, Yu X, et al. Association Between Pelvic Inflammatory Disease and Risk of Endometriosis: A Systematic Review and Meta-Analysis. J Womens Health (Larchmt) 2024; 33:73.</a></li><li><a class="nounderline abstract_t">Ness RB, Randall H, Richter HE, et al. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease. Am J Public Health 2004; 94:1327.</a></li><li><a class="nounderline abstract_t">Peipert LJ, Collins KE, Zhao Q, Peipert JF. Copper intrauterine device and incident sexually transmitted infections. Am J Obstet Gynecol 2021; 225:579.</a></li><li><a class="nounderline abstract_t">Wølner-Hanssen P, Eschenbach DA, Paavonen J, et al. Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA 1990; 263:54.</a></li><li><a class="nounderline abstract_t">Spinillo A, Gorini G, Piazzi G, et al. The impact of oral contraception on chlamydial infection among patients with pelvic inflammatory disease. Contraception 1996; 54:163.</a></li><li><a class="nounderline abstract_t">Ness RB, Soper DE, Holley RL, et al. Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study. Am J Obstet Gynecol 2001; 185:121.</a></li></ol></div><div id="topicVersionRevision">Topic 5469 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166300" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21199980" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Adverse adolescent reproductive health outcomes after pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12916126" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A refined estimate of the average lifetime cost of pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015517" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/123123" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effect of acute pelvic inflammatory disease on fertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15849530" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Predictors of chronic pelvic pain in an urban population of women with symptoms and signs of pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844746" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Recurrent PID, subsequent STI, and reproductive health outcomes: findings from the PID evaluation and clinical health (PEACH) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26579800" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Correlation Between Bladder Pain Syndrome/Interstitial Cystitis and Pelvic Inflammatory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8362945" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Atypical pelvic inflammatory disease: can we identify clinical predictors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10325271" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pregnancy rates after in-vitro fertilization in cases of tubal infertility with and without hydrosalpinx: a meta-analysis of published comparative studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23812461" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Tubal factor infertility and perinatal risk after assisted reproductive technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1411832" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22678036" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Subclinical pelvic inflammatory disease and infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17548070" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mycoplasma genitalium, Chlamydia trachomatis, and tubal factor infertility--a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135590" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effectiveness of treatment strategies of some women with pelvic inflammatory disease: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18300379" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Chlamydia antibodies, chlamydia heat shock protein, and adverse sequelae after pelvic inflammatory disease: the PID Evaluation and Clinical Health (PEACH) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33716075" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Intrauterine device use, sexually transmitted infections, and fertility: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8498436" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7008604" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9609570" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Severity of pelvic inflammatory disease as a predictor of the probability of live birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27272680" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chronic Pelvic Inflammation Diminished Ovarian Reserve as Indicated by Serum Anti Mülerrian Hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17531233" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Increased expression of uteroglobin associated with tubal inflammation and ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32037193" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21835693" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37778677" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pelvic inflammatory disease and risk of epithelial ovarian cancer: a national population-based case-control study in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28529540" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33418235" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Association between pelvic inflammatory disease and subsequent salpingectomy on the risk for ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37851499" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association Between Pelvic Inflammatory Disease and Risk of Endometriosis: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284036" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34363781" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Copper intrauterine device and incident sexually transmitted infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2293688" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8899258" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The impact of oral contraception on chlamydial infection among patients with pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11483915" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
